Gilead Sciences announced on Sunday that the UAE Ministry of Health and Prevention had granted regulatory approval for the coronavirus drug remdesivir.
The drug was approved as an emergency medicine to treat those suffering from COVID-19 infection, a statement read.
The approval was given following clinical data obtained in a trial by the US National Institute of Allergy & Infectious Diseases (NIAID).
The news follows a similar announcement Friday by the European Commission, which authorized the use of remdesivir to treat coronavirus.
At least two major US studies have shown that Remdesivir can reduce the duration of hospital stays for COVID-19 patients.
Washington authorized the emergency use of the medicine – which was originally intended as a treatment for Ebola – on May 1, followed by several Asian nations including Japan and South Korea.
The green light comes on the recommendation of the European Medicines Agency which gave its conditional authorization last week for the treatment of patients above 12 years of age who are suffering pneumonia and require extra oxygen.
It said its assessment was also mainly based on data from the NIAID study.
The research, published in the leading journal the New England Journal of Medicine in May, showed that injections of Remdesivir speeded patient recovery compared with a placebo.
On average it reduced patients’ hospital stays from 15 days to 11.
Coronavirus: EU approves anti-viral drug Remdesivir to treat COVID-19The European Commission, the bloc’s executive arm, on Friday authorized the use of anti-viral drug Remdesivir to treat the new coronavirus.For more ... Coronavirus
Coronavirus: Gilead COVID-19 drug remdesivir to cost $2,340 per patientThe maker of a drug shown to shorten recovery time for severely ill COVID-19 patients says it will charge $2,340 for a typical treatment course for ... Coronavirus
Coronavirus: US drug pricing group raises price advisory for Gilead’s remdesivirGilead Sciences Inc’s antiviral remdesivir could be priced up to $5,080 per course based on benefits shown in COVID-19 patients, a US drug pricing ... Coronavirus